Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy

Nutlins were identified as the first potent and specific small molecule Mdm2 antagonists that inhibit the p53- Mdm2 interaction. We show in this study that Nutlin-3 can downregulate TNFα induced activation of the NF-κB reporter in lung cancer cells. Activation of p53 dependent transcription is not compromised when Nutlin-3 is combined with TNFα. Instead, this combination treatment decreases cell viability in a p53 dependent manner. We show that Nutlin-3 strikingly inhibits the protein expression of NF-κB target genes ICAM-1 and MCP-1 while other targets like Bcl-xL and FLIP are not affected, thereby suggesting that the inhibition is promoter specific. This inhibition of ICAM-1 and MCP-1 by Nutlin-3 is again dependent on the p53 status in cells. Furthermore, we show that Nutlin-3 strongly inhibits protein expression of ICAM-1 and MCP-1 induced by IL1, another NF-κB activating stimuli. Nutlin-3 does not inhibit Akt phosphorylation, IκBα phosphorylation, IκBα degradation, p65 modification or p65 DNA binding in the cell lines tested. This study suggests the potential of Nutlin-3 as a bitargeted anti-cancer drug by simultaneously causing p53 activation and NF-κB suppression. It also suggests that Nutlin-3 could be evaluated for treatment of lung cancer as a single agent or in combination therapy by targeting its effect on ICAM-1 and MCP-1 which are known to be critical for cancer cell invasion, thereby downregulating tumor formation and metastasis. This study also suggests biomarkers of response for evaluation of Nutlin-3 in the clinic.

[1]  C. White,et al.  Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. , 1997, The Journal of biological chemistry.

[2]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[3]  S. Ghosh,et al.  Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. , 1998, Molecular cell.

[4]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[5]  T. Hupp,et al.  DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site , 1998, Oncogene.

[6]  R. Bargou,et al.  Selective Pharmacologic Activation of the p53-Dependent Pathway as a Therapeutic Strategy for Hematologic Malignancies , 2006, Cell cycle.

[7]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[8]  E. Leonard,et al.  Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. , 1993, Human pathology.

[9]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[10]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[11]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[12]  M. Hung,et al.  Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. , 2007, Molecular cell.

[13]  T. Gilmore,et al.  Inhibitors of NF-kappaB signaling: 785 and counting. , 2006, Oncogene.

[14]  F. Balkwill,et al.  Chemokine stimulation of monocyte matrix metalloproteinase‐9 requires endogenous TNF‐α  , 2002, European journal of immunology.

[15]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[17]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[18]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[19]  G. Stark,et al.  Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Fraser.  Exploring the Positive and Negative Consequences of NF-κB Inhibition for the Treatment of Human Disease , 2006, Cell cycle.

[21]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[22]  N. Perkins,et al.  Transcriptional cross talk between NF-kappaB and p53. , 1999, Molecular and cellular biology.

[23]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[24]  R. Terkeltaub,et al.  Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. , 1992, Journal of immunology.

[25]  G. Wahl,et al.  p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. , 2002, Cancer cell.

[26]  J. Johnson,et al.  12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. , 1994, The Journal of biological chemistry.

[27]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Chayama,et al.  Monocyte chemoattractant protein‐1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas , 2002, International journal of cancer.

[29]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[30]  C. Ballantyne,et al.  Increases in lung tissue expression of intercellular adhesion molecule-1 are associated with hyperoxic lung injury and inflammation in mice. , 1993, American journal of respiratory cell and molecular biology.

[31]  R. Strieter,et al.  Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. , 1998, Shock.

[32]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[33]  I. Verma,et al.  Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[35]  S. Ohno,et al.  NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. , 1994, Journal of immunology.

[36]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[37]  S. Ferrone,et al.  Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. , 1997, Cancer research.

[38]  A. J. Valente,et al.  Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[40]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[41]  P. Herrlich,et al.  UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells , 1989, Journal of virology.

[42]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[43]  Wei‐Chien Huang,et al.  Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. , 2004, Carcinogenesis.

[44]  D. Sampath,et al.  Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. , 1999, The Journal of clinical investigation.

[45]  R. Djukanović,et al.  The role of ICAM-1 on T-cells in the pathogenesis of asthma. , 1998, The European respiratory journal.

[46]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[47]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[48]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Long,et al.  Expression and regulation of adhesion molecules in cardiac cells by cytokines: response to acute hypoxia. , 1998, Circulation research.

[50]  Inder M Verma,et al.  A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[52]  W. Greene,et al.  Shaping the nuclear action of NF-kappaB. , 2004, Nature reviews. Molecular cell biology.

[53]  R. Nishikomori,et al.  Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. , 1994, Biochemical pharmacology.

[54]  N. Perkins,et al.  p53 and NF-kappaB crosstalk: IKKalpha tips the balance. , 2007, Molecular cell.

[55]  M. Konopleva,et al.  Concomitant Inhibition of MDM2 and Bcl-2 Protein Function Synergistically Induce Mitochondrial Apoptosis in AML , 2006, Cell cycle.

[56]  N. Ueda,et al.  Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. , 1995, Journal of Biological Chemistry.